Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Cantor Fitzgerald Reiterates Overweight on Health Catalyst, Maintains $16 Price Target

Author: Benzinga Newsdesk | March 05, 2024 01:37pm
Cantor Fitzgerald analyst Sarah James reiterates Health Catalyst (NASDAQ:HCAT) with a Overweight and maintains $16 price target.

Posted In: HCAT

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist